Biomarin Pharmaceutical (BMRN) Inventory Average (2010 - 2026)

Biomarin Pharmaceutical (BMRN) has 17 years of Inventory Average data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Inventory Average rose 2.58% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 2.58% YoY) and the FY2025 annual result came in at $1.3 billion, up 8.19% from the prior year.
• Inventory Average declined to $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $1.4 billion in Q3 2025 to a low of $781.5 million in Q1 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2024 — Inventory Average rose 23.84% — and 2026, when it gained 2.58%.
• Tracing BMRN's Inventory Average over 5 years: stood at $866.8 million in 2022, then advanced by 23.41% to $1.1 billion in 2023, then grew by 12.74% to $1.2 billion in 2024, then rose by 11.16% to $1.3 billion in 2025, then fell by 4.06% to $1.3 billion in 2026.
• The last three Inventory Average figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.